Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRI-VENT FSGS: Preemptive Rituximab for Recurrent FSGS
NCT03763643Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Jul 2019
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in focal segmental glomerulosclerosis (FSGS) comparing Rituximab + plasmapharesis with Placebo + plasmapharesis (2 arms). Primary endpoint: Feasibility assessment at 1 year. Started Jul 2019; status: completed.
02
Drugs
rituximab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03763643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03763643.